Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy.
Cancer therapy
Cell membrane coating
Dendritic cell biomimetic nanoparticles
Hybrid cell membrane
Immunotherapy
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
27 Oct 2024
27 Oct 2024
Historique:
received:
17
05
2024
accepted:
07
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Targeted immunotherapies make substantial strides in clinical cancer care due to their ability to counteract the tumor's capacity to suppress immune responses. Advances in biomimetic technology with minimally immunogenic and highly targeted, are addressing issues of targeted drug delivery and disrupting the tumor's immunosuppressive environment to trigger immune activation. Specifically, the use of dendritic cell (DC) membranes to coat nanoparticles ensures targeted delivery due to DC's unique ability to activate naive T cells, spotlighting their role in immunotherapy aimed at disrupting the tumor microenvironment. The potential of DC's biomimetic membrane to mediate immune activation and target tumors is gaining momentum, enhancing the effectiveness of cancer treatments in conjunction with other immune responses. This review delves into the methodologies behind crafting DC membranes and the fusion of dendritic and tumor cell membranes for encapsulating therapeutic nanoparticles. It explores their applications and recent advancements in combating cancer, offering an all-encompassing perspective on DC biomimetic nanosystems, immunotherapy driven by antigen presentation, and the collaborative efforts of drug delivery in chemotherapy and photodynamic therapies. Current evidence shows promise in augmenting combined therapeutic approaches for cancer treatment and holds translational potential for various cancer treatments in a clinical setting.
Identifiants
pubmed: 39465376
doi: 10.1186/s12951-024-02913-7
pii: 10.1186/s12951-024-02913-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
663Subventions
Organisme : National Natural Science Foundation of China
ID : 82370425
Informations de copyright
© 2024. The Author(s).
Références
Li A, Zhao Y, Li Y, Jiang L, Gu Y, Liu J. Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles. Drug Deliv. 2021;28:1237–55.
pubmed: 34142930
pmcid: 8216268
doi: 10.1080/10717544.2021.1938757
Roma-Rodrigues C, Pombo I, Raposo L, Pedrosa P, Fernandes AR, Baptista PV. Nanotheranostics targeting the tumor microenvironment. Front Bioeng Biotechnol. 2019;7:197.
pubmed: 31475143
pmcid: 6703081
doi: 10.3389/fbioe.2019.00197
The L. GLOBOCAN 2018: counting the toll of cancer. Lancet. 2018;392:985.
doi: 10.1016/S0140-6736(18)32252-9
Hu D, Sheng Z, Gao G, Siu F, Liu C, Wan Q, et al. Activatable albumin-photosensitizer nanoassemblies for triple-modal imaging and thermal-modulated photodynamic therapy of cancer. Biomaterials. 2016;93:10–9.
pubmed: 27061266
doi: 10.1016/j.biomaterials.2016.03.037
Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14:85.
pubmed: 34059100
pmcid: 8165984
doi: 10.1186/s13045-021-01096-0
Quesada JR, Hersh EM, Manning J, Reuben J, Keating M, Schnipper E, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood. 1986;68:493–7.
pubmed: 3730612
doi: 10.1182/blood.V68.2.493.493
Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–8.
pubmed: 24907378
doi: 10.4049/jimmunol.1490019
Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70:86–104.
pubmed: 31944278
doi: 10.3322/caac.21596
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, et al. Efficacy and safety of nivolumab plus Ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021;27:78–86.
pubmed: 32873572
doi: 10.1158/1078-0432.CCR-20-2063
André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022;33:1052–60.
pubmed: 35764271
doi: 10.1016/j.annonc.2022.06.008
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020–31.
pubmed: 31562796
doi: 10.1056/NEJMoa1910231
Sové RJ, Verma BK, Wang H, Ho WJ, Yarchoan M, Popel AS. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. J Immunother Cancer. 2022;10: e005414.
pubmed: 36323435
pmcid: 9639136
doi: 10.1136/jitc-2022-005414
Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022;28:1199–206.
pubmed: 35618839
doi: 10.1038/s41591-022-01821-3
Hargadon KM. Tumor microenvironmental influences on dendritic cell and T cell function: a focus on clinically relevant immunologic and metabolic checkpoints. Clin Transl Med. 2020;10:374–411.
pubmed: 32508018
pmcid: 7240858
doi: 10.1002/ctm2.37
Wong JL, Obermajer N, Odunsi K, Edwards RP, Kalinski P. Synergistic COX2 induction by IFNγ and TNFα Self-limits type-1 immunity in the human tumor microenvironment. Cancer Immunol Res. 2016;4:303–11.
pubmed: 26817996
pmcid: 4877699
doi: 10.1158/2326-6066.CIR-15-0157
Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity. 2019;50:1498-1512.e5.
pubmed: 31097342
pmcid: 6527362
doi: 10.1016/j.immuni.2019.04.010
Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014;26:623–37.
pubmed: 25446896
pmcid: 4254570
doi: 10.1016/j.ccell.2014.09.006
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity. 2018;49:1148-1161.e7.
pubmed: 30552023
pmcid: 6301092
doi: 10.1016/j.immuni.2018.09.024
Andzinski L, Spanier J, Kasnitz N, Kröger A, Jin L, Brinkmann MM, et al. Growing tumors induce a local STING dependent Type I IFN response in dendritic cells. Int J Cancer. 2016;139:1350–7.
pubmed: 27116225
doi: 10.1002/ijc.30159
Hilligan KL, Ronchese F. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses. Cell Mol Immunol. 2020;17:587–99.
pubmed: 32433540
pmcid: 7264306
doi: 10.1038/s41423-020-0465-0
Jego G, Pascual V, Palucka AK, Banchereau J. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun. 2005;8:124–39.
pubmed: 15564719
doi: 10.1159/000082101
Münz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood. 2005;105:266–73.
pubmed: 15331446
doi: 10.1182/blood-2004-06-2492
Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27:74–95.
pubmed: 28025976
doi: 10.1038/cr.2016.157
Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37:855–65.
pubmed: 27793569
pmcid: 5135568
doi: 10.1016/j.it.2016.09.006
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396–401.
pubmed: 27281205
doi: 10.1038/nature18300
Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175–96.
pubmed: 30622344
pmcid: 6410566
doi: 10.1038/s41573-018-0006-z
Ma J, Liu F, Sheu WC, Meng Z, Xie Y, Xu H, et al. Copresentation of tumor antigens and costimulatory molecules via biomimetic nanoparticles for effective cancer immunotherapy. Nano Lett. 2020;20:4084–94.
pubmed: 32379462
doi: 10.1021/acs.nanolett.9b05171
Fang RH, Kroll AV, Gao W, Zhang L. Cell membrane coating nanotechnology. Adv Mater. 2018;30: e1706759.
pubmed: 29582476
pmcid: 5984176
doi: 10.1002/adma.201706759
Oroojalian F, Beygi M, Baradaran B, Mokhtarzadeh A, Shahbazi MA. Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy. Small. 2021;17: e2006484.
pubmed: 33577127
doi: 10.1002/smll.202006484
Fang RH, Jiang Y, Fang JC, Zhang L. Cell membrane-derived nanomaterials for biomedical applications. Biomaterials. 2017;128:69–83.
pubmed: 28292726
pmcid: 5417338
doi: 10.1016/j.biomaterials.2017.02.041
Cheng S, Xu C, Jin Y, Li Y, Zhong C, Ma J, et al. Artificial mini dendritic cells boost T cell-based immunotherapy for ovarian cancer. Adv Sci. 2020;7:1903301.
doi: 10.1002/advs.201903301
Ahire E, Thakkar S, Darshanwad M, Misra M. Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications. Acta Pharm Sin B. 2018;8:733–55.
pubmed: 30245962
pmcid: 6146387
doi: 10.1016/j.apsb.2018.07.011
Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2023;20:33–48.
pubmed: 36307534
doi: 10.1038/s41571-022-00699-x
Huang Y, Gao X, Chen J. Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. Acta Pharm Sin B. 2018;8:4–13.
pubmed: 29872618
pmcid: 5985693
doi: 10.1016/j.apsb.2017.12.001
Fliervoet LAL, Mastrobattista E. Drug delivery with living cells. Adv Drug Deliv Rev. 2016;106:63–72.
pubmed: 27129442
doi: 10.1016/j.addr.2016.04.021
Han X, Shen S, Fan Q, Chen G, Archibong E, Dotti G, et al. Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. Sci Adv. 2019;5:6870.
doi: 10.1126/sciadv.aaw6870
Parodi A, Quattrocchi N, van de Ven AL, Chiappini C, Evangelopoulos M, Martinez JO, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol. 2013;8:61–8.
pubmed: 23241654
doi: 10.1038/nnano.2012.212
Wang H, Wu J, Williams GR, Fan Q, Niu S, Wu J, et al. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J Nanobiotechnology. 2019;17:60.
pubmed: 31084622
pmcid: 6513513
doi: 10.1186/s12951-019-0494-y
Chen Z, Zhao P, Luo Z, Zheng M, Tian H, Gong P, et al. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano. 2016;10:10049–57.
pubmed: 27934074
doi: 10.1021/acsnano.6b04695
Zhang Y, Cai K, Li C, Guo Q, Chen Q, He X, et al. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy. Nano Lett. 2018;18:1908–15.
pubmed: 29473753
pmcid: 7470025
doi: 10.1021/acs.nanolett.7b05263
Li YS, Wu HH, Jiang XC, Zhang TY, Zhou Y, Huang LL, et al. Active stealth and self-positioning biomimetic vehicles achieved effective antitumor therapy. J Control Release. 2021;335:515–26.
pubmed: 34058269
doi: 10.1016/j.jconrel.2021.05.031
Xiong J, Wu M, Chen J, Liu Y, Chen Y, Fan G, et al. Cancer-erythrocyte hybrid membrane-camouflaged magnetic nanoparticles with enhanced photothermal-immunotherapy for ovarian cancer. ACS Nano. 2021;15:19756–70.
pubmed: 34860006
doi: 10.1021/acsnano.1c07180
Han H, Bártolo R, Li J, Shahbazi MA, Santos HA. Biomimetic platelet membrane-coated nanoparticles for targeted therapy. Eur J Pharm Biopharm. 2022;172:1–15.
pubmed: 35074554
doi: 10.1016/j.ejpb.2022.01.004
Verneau J, Sautés-Fridman C, Sun CM. Dendritic cells in the tumor microenvironment: prognostic and theranostic impact. Semin Immunol. 2020;48: 101410.
pubmed: 33011065
doi: 10.1016/j.smim.2020.101410
Eisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol. 2019;19:89–103.
pubmed: 30464294
pmcid: 7755085
doi: 10.1038/s41577-018-0088-1
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–22.
pubmed: 24048123
pmcid: 4118725
doi: 10.1038/ni.2703
Li Y, Tang K, Zhang X, Pan W, Li N, Tang B. A dendritic cell-like biomimetic nanoparticle enhances T cell activation for breast cancer immunotherapy. Chem Sci. 2021;13:105–10.
pubmed: 35059157
pmcid: 8694320
doi: 10.1039/D1SC03525H
Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. morphology, quantitation, tissue distribution. J Exp Med. 1973;137:1142–62.
pubmed: 4573839
pmcid: 2139237
doi: 10.1084/jem.137.5.1142
Cantor H, Boyse EA. Functional subclasses of T lymphocytes bearing different Ly antigens. II. Cooperation between subclasses of Ly+ cells in the generation of killer activity. J Exp Med. 1975;141:1390–9.
pubmed: 1092799
doi: 10.1084/jem.141.6.1390
Hao W, Cui Y, Fan Y, Chen M, Yang G, Wang Y, et al. Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery. J Nanobiotechnology. 2021;19:378.
pubmed: 34801032
pmcid: 8606100
doi: 10.1186/s12951-021-01110-0
Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16:599–611.
pubmed: 27526640
doi: 10.1038/nri.2016.80
Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18:635–47.
pubmed: 30057419
doi: 10.1038/s41577-018-0044-0
Ahrends T, Spanjaard A, Pilzecker B, Bąbała N, Bovens A, Xiao Y, et al. CD4(+) T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity. 2017;47:848-861.e5.
pubmed: 29126798
doi: 10.1016/j.immuni.2017.10.009
Oh DY, Fong L. Cytotoxic CD4(+) T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54:2701–11.
pubmed: 34910940
pmcid: 8809482
doi: 10.1016/j.immuni.2021.11.015
Gardner A, de Mingo PA, Ruffell B. Dendritic cells and their role in immunotherapy. Front Immunol. 2020;11:924.
pubmed: 32508825
pmcid: 7253577
doi: 10.3389/fimmu.2020.00924
Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto JAM. Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. Front Immunol. 2018;9:3176.
pubmed: 30719026
doi: 10.3389/fimmu.2018.03176
Fu C, Zhou L, Mi QS, Jiang A. Plasmacytoid dendritic cells and cancer immunotherapy. Cells. 2022;11:222.
pubmed: 35053338
pmcid: 8773673
doi: 10.3390/cells11020222
Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154:3–20.
pubmed: 29313948
pmcid: 5904714
doi: 10.1111/imm.12888
Schlitzer A, McGovern N, Ginhoux F. Dendritic cells and monocyte-derived cells: two complementary and integrated functional systems. Semin Cell Dev Biol. 2015;41:9–22.
pubmed: 25957517
doi: 10.1016/j.semcdb.2015.03.011
Fu C, Jiang A. Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front Immunol. 2018;9:3059.
pubmed: 30619378
pmcid: 6306491
doi: 10.3389/fimmu.2018.03059
Murphy TL, Murphy KM. Dendritic cells in cancer immunology. Cell Mol Immunol. 2022;19:3–13.
pubmed: 34480145
doi: 10.1038/s41423-021-00741-5
Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, Yao K, et al. In vivo analysis of dendritic cell development and homeostasis. Science. 2009;324:392–7.
pubmed: 19286519
pmcid: 2803315
doi: 10.1126/science.1170540
Macri C, Pang ES, Patton T, O’Keeffe M. Dendritic cell subsets. Semin Cell Dev Biol. 2018;84:11–21.
pubmed: 29246859
doi: 10.1016/j.semcdb.2017.12.009
Bamboat ZM, Stableford JA, Plitas G, Burt BM, Nguyen HM, Welles AP, et al. Human liver dendritic cells promote T cell hyporesponsiveness. J Immunol. 2009;182:1901–11.
pubmed: 19201843
doi: 10.4049/jimmunol.0803404
Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity. 2012;37:60–73.
pubmed: 22795876
pmcid: 3476529
doi: 10.1016/j.immuni.2012.04.012
Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207:1247–60.
pubmed: 20479116
pmcid: 2882828
doi: 10.1084/jem.20092140
Poulin LF, Reyal Y, Uronen-Hansson H, Schraml BU, Sancho D, Murphy KM, et al. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood. 2012;119:6052–62.
pubmed: 22442345
doi: 10.1182/blood-2012-01-406967
Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010;207:1261–71.
pubmed: 20479117
pmcid: 2882845
doi: 10.1084/jem.20092618
Meixlsperger S, Leung CS, Rämer PC, Pack M, Vanoaica LD, Breton G, et al. CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood. 2013;121:5034–44.
pubmed: 23482932
pmcid: 3689250
doi: 10.1182/blood-2012-12-473413
Mittag D, Proietto AI, Loudovaris T, Mannering SI, Vremec D, Shortman K, et al. Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J Immunol. 2011;186:6207–17.
pubmed: 21515786
doi: 10.4049/jimmunol.1002632
Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000;165:6037–46.
pubmed: 11086035
doi: 10.4049/jimmunol.165.11.6037
MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human blood dendritic cell subsets. Blood. 2002;100:4512–20.
pubmed: 12393628
doi: 10.1182/blood-2001-11-0097
Watchmaker PB, Lahl K, Lee M, Baumjohann D, Morton J, Kim SJ, et al. Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Nat Immunol. 2014;15:98–108.
pubmed: 24292363
doi: 10.1038/ni.2768
Brandum EP, Jørgensen AS, Rosenkilde MM, Hjortø GM. Dendritic cells and CCR7 expression: an important factor for autoimmune diseases, chronic inflammation, and cancer. Int J Mol Sci. 2021;22:8340.
pubmed: 34361107
pmcid: 8348795
doi: 10.3390/ijms22158340
Zelenay S, Reise SC. Adaptive immunity after cell death. Trends Immunol. 2013;34:329–35.
pubmed: 23608152
doi: 10.1016/j.it.2013.03.005
Böttcher JP, Reise SC. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4:784–92.
pubmed: 30352680
pmcid: 6207145
doi: 10.1016/j.trecan.2018.09.001
Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72.
pubmed: 28555670
pmcid: 5731833
doi: 10.1038/nri.2017.49
Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172:1022-1037.e14.
pubmed: 29429633
pmcid: 5847168
doi: 10.1016/j.cell.2018.01.004
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24:1178–91.
pubmed: 29942093
pmcid: 6475503
doi: 10.1038/s41591-018-0085-8
Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345–59.
pubmed: 33837297
pmcid: 8034277
doi: 10.1038/s41568-021-00347-z
Li YL, Hung WC. Reprogramming of sentinel lymph node microenvironment during tumor metastasis. J Biomed Sci. 2022;29:84.
pubmed: 36266717
pmcid: 9583492
doi: 10.1186/s12929-022-00868-1
Wang Q, Wang Z, Sun X, Jiang Q, Sun B, He Z, et al. Lymph node-targeting nanovaccines for cancer immunotherapy. J Control Release. 2022;351:102–22.
pubmed: 36115556
doi: 10.1016/j.jconrel.2022.09.015
Cai T, Liu H, Zhang S, Hu J, Zhang L. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy. J Nanobiotechnology. 2021;19:389.
pubmed: 34823541
pmcid: 8620195
doi: 10.1186/s12951-021-01146-2
Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y, et al. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 2020;30:229–43.
pubmed: 32094452
pmcid: 7054407
doi: 10.1038/s41422-020-0287-8
Seyfizadeh N, Muthuswamy R, Mitchell DA, Nierkens S, Seyfizadeh N. Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses. Crit Rev Oncol Hematol. 2016;107:100–10.
pubmed: 27823637
doi: 10.1016/j.critrevonc.2016.09.002
Schineis P, Runge P, Halin C. Cellular traffic through afferent lymphatic vessels. Vascul Pharmacol. 2019;112:31–41.
pubmed: 30092362
doi: 10.1016/j.vph.2018.08.001
Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol. 1998;28:2760–9.
pubmed: 9754563
doi: 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N
Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45–56.
pubmed: 31578484
doi: 10.1038/s41586-019-1593-5
Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44:924–38.
pubmed: 27096321
pmcid: 4980762
doi: 10.1016/j.immuni.2016.03.012
Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30:324–36.
pubmed: 27424807
pmcid: 5374862
doi: 10.1016/j.ccell.2016.06.003
Weber M, Hauschild R, Schwarz J, Moussion C, de Vries I, Legler DF, et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science. 2013;339:328–32.
pubmed: 23329049
doi: 10.1126/science.1228456
Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol. 2004;14:181–5.
pubmed: 15246053
doi: 10.1016/j.semcancer.2003.10.004
Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119:2026–9.
pubmed: 16671092
doi: 10.1002/ijc.22024
Penna G, Vulcano M, Sozzani S, Adorini L. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Hum Immunol. 2002;63:1164–71.
pubmed: 12480260
doi: 10.1016/S0198-8859(02)00755-3
Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011;208:2005–16.
pubmed: 21930765
pmcid: 3182064
doi: 10.1084/jem.20101159
Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016;126:2404–11.
pubmed: 27367184
pmcid: 4922692
doi: 10.1172/JCI86892
Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017;45:43–51.
pubmed: 28192720
pmcid: 5449252
doi: 10.1016/j.coi.2017.01.002
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989–2003.
pubmed: 21930769
pmcid: 3182061
doi: 10.1084/jem.20101158
Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013;34:67–73.
pubmed: 23122052
doi: 10.1016/j.it.2012.10.004
Brewitz A, Eickhoff S, Dähling S, Quast T, Bedoui S, Kroczek RA, et al. CD8(+) T cells orchestrate pDC-XCR1(+) dendritic cell spatial and functional cooperativity to optimize priming. Immunity. 2017;46:205–19.
pubmed: 28190711
pmcid: 5362251
doi: 10.1016/j.immuni.2017.01.003
Zong J, Keskinov AA, Shurin GV, Shurin MR. Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother. 2016;65:821–33.
pubmed: 26984847
pmcid: 11028482
doi: 10.1007/s00262-016-1820-y
Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, et al. cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity. Nature. 2020;584:624–9.
pubmed: 32788723
pmcid: 7469755
doi: 10.1038/s41586-020-2611-3
Hao T, Chen Q, Qi Y, Sun P, Chen D, Jiang W, et al. Biomineralized Gd(2) O(3) @HSA nanoparticles as a versatile platform for dual-modal imaging and chemo-phototherapy-synergized tumor ablation. Adv Healthc Mater. 2019;8: e1901005.
pubmed: 31738019
doi: 10.1002/adhm.201901005
Lokhov PG, Balashova EE. Antigenic essence: upgrade of cellular cancer vaccines. Cancers (Basel). 2021;13:774.
pubmed: 33673325
doi: 10.3390/cancers13040774
Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature. 2006;441:890–3.
pubmed: 16778891
pmcid: 2776073
doi: 10.1038/nature04790
Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 2002;297:2060–3.
pubmed: 12242444
doi: 10.1126/science.1072615
Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67.
pubmed: 29118008
doi: 10.1182/blood-2017-06-741033
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7–24.
pubmed: 31467405
doi: 10.1038/s41577-019-0210-z
Iwanowycz S, Ngoi S, Li Y, Hill M, Koivisto C, Parrish M, et al. Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors. JCI Insight. 2021. https://doi.org/10.1172/jci.insight.145885 .
doi: 10.1172/jci.insight.145885
pubmed: 34283809
pmcid: 8492342
Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood. 2013;122:932–42.
pubmed: 23794066
doi: 10.1182/blood-2013-04-495424
Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26:938.
pubmed: 28898680
doi: 10.1016/j.ccell.2014.11.010
den Haan JM, Bevan MJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med. 2002;196:817–27.
doi: 10.1084/jem.20020295
Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, et al. IgE/FcεRI-mediated antigen cross-presentation by dendritic cells enhances anti-tumor immune responses. Cell Rep. 2015;10:1487–95.
pubmed: 25753415
pmcid: 4559493
doi: 10.1016/j.celrep.2015.02.015
Sato T, Kitawaki T, Fujita H, Iwata M, Iyoda T, Inaba K, et al. Human CD1c⁺ myeloid dendritic cells acquire a high level of retinoic acid-producing capacity in response to vitamin D₃. J Immunol. 2013;191:3152–60.
pubmed: 23966631
doi: 10.4049/jimmunol.1203517
Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, et al. Unleashing Type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity. Cell. 2019;177:556-571.e16.
pubmed: 30955881
pmcid: 6954108
doi: 10.1016/j.cell.2019.02.005
Segura E, Valladeau-Guilemond J, Donnadieu MH, Sastre-Garau X, Soumelis V, Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med. 2012;209:653–60.
pubmed: 22430490
pmcid: 3328358
doi: 10.1084/jem.20111457
Leal Rojas IM, Mok WH, Pearson FE, Minoda Y, Kenna TJ, Barnard RT, et al. Human blood CD1c(+) dendritic cells promote Th1 and Th17 effector function in memory CD4(+) T cells. Front Immunol. 2017;8:971.
pubmed: 28878767
pmcid: 5572390
doi: 10.3389/fimmu.2017.00971
Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. Immunity. 2019;50:37–50.
pubmed: 30650380
pmcid: 6342491
doi: 10.1016/j.immuni.2018.12.027
Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity. 2003;19:59–70.
pubmed: 12871639
doi: 10.1016/S1074-7613(03)00171-7
Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell. 2016;30:377–90.
pubmed: 27622331
pmcid: 5023283
doi: 10.1016/j.ccell.2016.08.004
Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, et al. Activation of p53 in immature myeloid precursor cells controls differentiation into Ly6c(+)CD103(+) monocytic antigen-presenting cells in tumors. Immunity. 2018;48:91-106.e6.
pubmed: 29343444
pmcid: 6005382
doi: 10.1016/j.immuni.2017.12.014
Chiang MC, Tullett KM, Lee YS, Idris A, Ding Y, McDonald KJ, et al. Differential uptake and cross-presentation of soluble and necrotic cell antigen by human DC subsets. Eur J Immunol. 2016;46:329–39.
pubmed: 26542182
doi: 10.1002/eji.201546023
León B, López-Bravo M, Ardavín C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity. 2007;26:519–31.
pubmed: 17412618
doi: 10.1016/j.immuni.2007.01.017
Martínez-López M, Iborra S, Conde-Garrosa R, Sancho D. Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice. Eur J Immunol. 2015;45:119–29.
pubmed: 25312824
doi: 10.1002/eji.201444651
Brown CC, Gudjonson H, Pritykin Y, Deep D, Lavallée VP, Mendoza A, et al. Transcriptional basis of mouse and human dendritic cell heterogeneity. Cell. 2019;179:846-863.e24.
pubmed: 31668803
pmcid: 6838684
doi: 10.1016/j.cell.2019.09.035
Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity. 2008;29:352–61.
pubmed: 18799143
doi: 10.1016/j.immuni.2008.09.002
McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol. 2005;79:17–27.
pubmed: 15596797
pmcid: 538703
doi: 10.1128/JVI.79.1.17-27.2005
Swiecki M, Colonna M. Accumulation of plasmacytoid DC: roles in disease pathogenesis and targets for immunotherapy. Eur J Immunol. 2010;40:2094–8.
pubmed: 20853492
pmcid: 3732170
doi: 10.1002/eji.201040602
Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15:471–85.
pubmed: 26160613
pmcid: 4808588
doi: 10.1038/nri3865
Saadeh D, Kurban M, Abbas O. Plasmacytoid dendritic cell role in cutaneous malignancies. J Dermatol Sci. 2016;83:3–9.
pubmed: 27236509
doi: 10.1016/j.jdermsci.2016.05.008
Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol. 2003;33:1052–62.
pubmed: 12672071
doi: 10.1002/eji.200323676
Lombardi VC, Khaiboullina SF, Rizvanov AA. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression. Eur J Clin Invest. 2015;45(Suppl 1):1–8.
pubmed: 25524580
doi: 10.1111/eci.12363
Dress RJ, Dutertre CA, Giladi A, Schlitzer A, Low I, Shadan NB, et al. Plasmacytoid dendritic cells develop from Ly6D(+) lymphoid progenitors distinct from the myeloid lineage. Nat Immunol. 2019;20:852–64.
pubmed: 31213723
doi: 10.1038/s41590-019-0420-3
Rodrigues PF, Alberti-Servera L, Eremin A, Grajales-Reyes GE, Ivanek R, Tussiwand R. Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells. Nat Immunol. 2018;19:711–22.
pubmed: 29925996
pmcid: 7614340
doi: 10.1038/s41590-018-0136-9
Wenzel J, Bekisch B, Uerlich M, Haller O, Bieber T, Tüting T. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol. 2005;124:37–48.
pubmed: 15923172
doi: 10.1309/4EJ9KL7CGDENVVLE
Cohn L, Chatterjee B, Esselborn F, Smed-Sörensen A, Nakamura N, Chalouni C, et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med. 2013;210:1049–63.
pubmed: 23569326
pmcid: 3646496
doi: 10.1084/jem.20121251
Anderson DA 3rd, Dutertre CA, Ginhoux F, Murphy KM. Genetic models of human and mouse dendritic cell development and function. Nat Rev Immunol. 2021;21:101–15.
pubmed: 32908299
doi: 10.1038/s41577-020-00413-x
Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012;72:5188–97.
pubmed: 22836755
doi: 10.1158/0008-5472.CAN-11-3468
Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med. 2007;5:62.
pubmed: 18047662
pmcid: 2212626
doi: 10.1186/1479-5876-5-62
Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology. 2012;1:380–2.
pubmed: 22737622
pmcid: 3382863
doi: 10.4161/onci.18801
Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003;63:6478–87.
pubmed: 14559840
Demoulin S, Herfs M, Delvenne P, Hubert P. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol. 2013;93:343–52.
pubmed: 23136258
doi: 10.1189/jlb.0812397
Gerlini G, Urso C, Mariotti G, Di Gennaro P, Palli D, Brandani P, et al. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol. 2007;125:184–93.
pubmed: 17827069
doi: 10.1016/j.clim.2007.07.018
Battaglia A, Buzzonetti A, Baranello C, Ferrandina G, Martinelli E, Fanfani F, et al. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother. 2009;58:1363–73.
pubmed: 19172271
pmcid: 11030623
doi: 10.1007/s00262-008-0646-7
Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117:2570–82.
pubmed: 17710230
pmcid: 1940240
doi: 10.1172/JCI31911
Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280–90.
pubmed: 15254595
pmcid: 449750
doi: 10.1172/JCI21583
Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762–74.
pubmed: 15459668
doi: 10.1038/nri1457
Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med. 2004;10:15–8.
pubmed: 14720581
doi: 10.1016/j.molmed.2003.11.003
Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 2005;105:1162–9.
pubmed: 15479730
doi: 10.1182/blood-2004-03-1211
Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213–22.
pubmed: 11067871
pmcid: 2193357
doi: 10.1084/jem.192.9.1213
Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 2011;71:5423–34.
pubmed: 21697280
doi: 10.1158/0008-5472.CAN-11-0367
Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol. 2007;82:1365–74.
pubmed: 17711977
doi: 10.1189/jlb.0307166
Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239–44.
pubmed: 18285775
pmcid: 3075612
doi: 10.1038/ni1572
Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, Boor PP, Mancham S, Verhoef C, et al. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncoimmunology. 2015;4: e1008355.
pubmed: 26155417
pmcid: 4485712
doi: 10.1080/2162402X.2015.1008355
Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med. 2007;204:105–15.
pubmed: 17200410
pmcid: 2118437
doi: 10.1084/jem.20061660
Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38:729–41.
pubmed: 23562161
doi: 10.1016/j.immuni.2013.03.003
Koerner J, Horvath D, Groettrup M. Harnessing dendritic cells for poly (D, L-lactide-co-glycolide) microspheres (PLGA MS)-mediated anti-tumor therapy. Front Immunol. 2019;10:707.
pubmed: 31024545
pmcid: 6460768
doi: 10.3389/fimmu.2019.00707
Kim HS, Ho TC, Willner MJ, Becker MW, Kim HW, Leong KW. Dendritic cell-mimicking scaffolds for ex vivo T cell expansion. Bioact Mater. 2023;21:241–52.
pubmed: 36157246
Jugniot N, Dahl JJ, Paulmurugan R. Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy. J Exp Clin Cancer Res. 2022;41:299.
pubmed: 36224614
pmcid: 9555090
doi: 10.1186/s13046-022-02501-3
Lopes J, Lopes D, Pereira-Silva M, Peixoto D, Veiga F, Hamblin MR, et al. Macrophage cell membrane-cloaked nanoplatforms for biomedical applications. Small Methods. 2022;6: e2200289.
pubmed: 35768282
doi: 10.1002/smtd.202200289
Suzuki KG. New insights into the organization of plasma membrane and its role in signal transduction. Int Rev Cell Mol Biol. 2015;317:67–96.
pubmed: 26008784
doi: 10.1016/bs.ircmb.2015.02.004
Ma X, Kuang L, Yin Y, Tang L, Zhang Y, Fan Q, et al. Tumor-antigen activated dendritic cell membrane-coated biomimetic nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma. ACS Nano. 2023;17:2341–55.
pubmed: 36688797
doi: 10.1021/acsnano.2c09033
Sun Z, Deng G, Peng X, Xu X, Liu L, Peng J, et al. Intelligent photothermal dendritic cells restart the cancer immunity cycle through enhanced immunogenic cell death. Biomaterials. 2021;279: 121228.
pubmed: 34717198
doi: 10.1016/j.biomaterials.2021.121228
Liu WL, Zou MZ, Liu T, Zeng JY, Li X, Yu WY, et al. Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells. Nat Commun. 2019;10:3199.
pubmed: 31324770
pmcid: 6642123
doi: 10.1038/s41467-019-11157-1
Liu WL, Zou MZ, Liu T, Zeng JY, Li X, Yu WY, et al. Expandable immunotherapeutic nanoplatforms engineered from cytomembranes of hybrid cells derived from cancer and dendritic cells. Adv Mater. 2019;31: e1900499.
pubmed: 30907473
doi: 10.1002/adma.201900499
Chen F, Geng Z, Wang L, Zhou Y, Liu J. Biomimetic nanoparticles enabled by cascade cell membrane coating for direct cross-priming of T cells. Small. 2022;18: e2104402.
pubmed: 34837321
doi: 10.1002/smll.202104402
Chen X, Ling X, Xia J, Zhu Y, Zhang L, He Y, et al. Mature dendritic cell-derived dendrosomes swallow oxaliplatin-loaded nanoparticles to boost immunogenic chemotherapy and tumor antigen-specific immunotherapy. Bioact Mater. 2022;15:15–28.
pubmed: 35386340
Zhou M, Xing Y, Li X, Du X, Xu T, Zhang X. Cancer cell Membrane camouflaged semi-yolk@spiky-shell nanomotor for enhanced cell adhesion and synergistic therapy. Small. 2020;16: e2003834.
pubmed: 32877017
doi: 10.1002/smll.202003834
Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479–85.
pubmed: 30894752
pmcid: 6954100
doi: 10.1038/s41586-019-1032-7
Koido S. Dendritic-tumor fusion cell-based cancer vaccines. Int J Mol Sci. 2016;17:828.
pubmed: 27240347
pmcid: 4926362
doi: 10.3390/ijms17060828
Zhang L, Zhao W, Huang J, Li F, Sheng J, Song H, et al. Development of a dendritic cell/Tumor cell fusion cell membrane nano-vaccine for the treatment of ovarian cancer. Front Immunol. 2022;13: 828263.
pubmed: 35251013
pmcid: 8893350
doi: 10.3389/fimmu.2022.828263
Yang X, Yu T, Zeng Y, Lian K, Zhou X, Ke J, et al. pH-responsive biomimetic polymeric micelles as lymph node-targeting vaccines for enhanced antitumor immune responses. Biomacromol. 2020;21:2818–28.
doi: 10.1021/acs.biomac.0c00518
Ma J, Zhang S, Liu J, Liu F, Du F, Li M, et al. Targeted drug delivery to stroke via chemotactic recruitment of nanoparticles coated with membrane of engineered neural stem cells. Small. 2019;15: e1902011.
pubmed: 31290245
pmcid: 11089900
doi: 10.1002/smll.201902011
Gandhi S, Shende P. Cyclodextrins-modified metallic nanoparticles for effective cancer therapy. J Control Release. 2021;339:41–50.
pubmed: 34560156
doi: 10.1016/j.jconrel.2021.09.025
Xu X, Deng G, Sun Z, Luo Y, Liu J, Yu X, et al. A biomimetic aggregation-induced emission photosensitizer with antigen-presenting and hitchhiking function for lipid droplet targeted photodynamic immunotherapy. Adv Mater. 2021;33: e2102322.
pubmed: 34247428
doi: 10.1002/adma.202102322
Su Y, Zhang B, Sun R, Liu W, Zhu Q, Zhang X, et al. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv. 2021;28:1397–418.
pubmed: 34184949
pmcid: 8248937
doi: 10.1080/10717544.2021.1938756
Hua Y, Su Y, Zhang H, Liu N, Wang Z, Gao X, et al. Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review. Drug Deliv. 2021;28:1342–55.
pubmed: 34180769
pmcid: 8245074
doi: 10.1080/10717544.2021.1943056
Jain AK, Das M, Swarnakar NK, Jain S. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit Rev Ther Drug Carrier Syst. 2011;28:1–45.
pubmed: 21395514
doi: 10.1615/CritRevTherDrugCarrierSyst.v28.i1.10
Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res. 2020;24:3.
pubmed: 31969986
pmcid: 6964012
doi: 10.1186/s40824-020-0184-8
Jin JO, Jang S, Kim H, Oh J, Shim S, Kwak M, et al. Immunostimulatory agent evaluation: lymphoid tissue extraction and injection route-dependent dendritic cell activation. J Vis Exp. 2018. https://doi.org/10.3791/57640 .
doi: 10.3791/57640
pubmed: 30417874
pmcid: 6235589
Howard GP, Verma G, Ke X, Thayer WM, Hamerly T, Baxter VK, et al. Critical size limit of biodegradable nanoparticles for enhanced lymph node trafficking and paracortex penetration. Nano Res. 2019;12:837–44.
pubmed: 33343832
pmcid: 7747954
doi: 10.1007/s12274-019-2301-3
Zhang YN, Lazarovits J, Poon W, Ouyang B, Nguyen LNM, Kingston BR, et al. Nanoparticle size influences antigen retention and presentation in lymph node follicles for humoral immunity. Nano Lett. 2019;19:7226–35.
pubmed: 31508968
doi: 10.1021/acs.nanolett.9b02834
Harvey BT, Fu X, Li L, Neupane KR, Anand N, Kolesar JM, et al. Dendritic cell membrane-derived nanovesicles for targeted T cell activation. ACS Omega. 2022;7:46222–33.
pubmed: 36570199
pmcid: 9773342
doi: 10.1021/acsomega.2c04420
Ochyl LJ, Moon JJ. Dendritic cell membrane vesicles for activation and maintenance of antigen-specific T cells. Adv Healthc Mater. 2019;8: e1801091.
pubmed: 30565895
doi: 10.1002/adhm.201801091
Peng W, Zhang Y, Zhu R, Mechref Y. Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis. Electrophoresis. 2017;38:2124–34.
pubmed: 28523741
doi: 10.1002/elps.201700027
Zhang D, Ye Z, Wei L, Luo H, Xiao L. Cell membrane-coated porphyrin metal-organic frameworks for cancer cell targeting and O(2)-evolving photodynamic therapy. ACS Appl Mater Interf. 2019;11:39594–602.
doi: 10.1021/acsami.9b14084
Harris JC, Scully MA, Day ES. Cancer cell membrane-coated nanoparticles for cancer management. Cancers (Basel). 2019;11:1836.
pubmed: 31766360
doi: 10.3390/cancers11121836
Fang RH, Hu CM, Luk BT, Gao W, Copp JA, Tai Y, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14:2181–8.
pubmed: 24673373
pmcid: 3985711
doi: 10.1021/nl500618u
Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023;20:265–78.
pubmed: 36781982
doi: 10.1038/s41571-023-00736-3
Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, et al. Remodeling tumor-associated neutrophils to enhance dendritic cell-based HCC neoantigen nano-vaccine efficiency. Adv Sci (Weinh). 2022;9: e2105631.
pubmed: 35142445
doi: 10.1002/advs.202105631
Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265–77.
pubmed: 22437871
pmcid: 3433802
doi: 10.1038/nrc3258
Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022;185(1694–1708): e19.
Yang J, Davis T, Kazerouni AS, Chen YI, Bloom MJ, Yeh HC, et al. Longitudinal FRET imaging of glucose and lactate dynamics and response to therapy in breast cancer cells. Mol Imaging Biol. 2022;24:144–55.
pubmed: 34611767
doi: 10.1007/s11307-021-01639-4
Du S, Liu Y, Yuan Y, Wang Y, Chen Y, Wang S, et al. Advances in the study of HSP70 inhibitors to enhance the sensitivity of tumor cells to radiotherapy. Front Cell Dev Biol. 2022;10: 942828.
pubmed: 36036010
pmcid: 9399644
doi: 10.3389/fcell.2022.942828
Liang X, Ye X, Wang C, Xing C, Miao Q, Xie Z, et al. Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. J Control Release. 2019;296:150–61.
pubmed: 30682441
doi: 10.1016/j.jconrel.2019.01.027
Azzi J, Yin Q, Uehara M, Ohori S, Tang L, Cai K, et al. Targeted delivery of immunomodulators to lymph nodes. Cell Rep. 2016;15:1202–13.
pubmed: 27134176
pmcid: 4973867
doi: 10.1016/j.celrep.2016.04.007
Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7:3–23.
pubmed: 30666921
pmcid: 6691849
doi: 10.2174/2211738507666190122111224
Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27.
pubmed: 31421262
doi: 10.1016/j.semcancer.2019.08.012
Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G, et al. Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality. Cancer Treat Rev. 2022;105: 102375.
pubmed: 35367784
doi: 10.1016/j.ctrv.2022.102375
Sevinsky CJ, Khan F, Kokabee L, Darehshouri A, Maddipati KR, Conklin DS. NDRG1 regulates neutral lipid metabolism in breast cancer cells. Breast Cancer Res. 2018;20:55.
pubmed: 29898756
pmcid: 6001025
doi: 10.1186/s13058-018-0980-4
Kwiatkowski S, Knap B, Przystupski D, Saczko J, Kedzierska E, Knap-Czop K, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098–107.
pubmed: 30119176
doi: 10.1016/j.biopha.2018.07.049
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
pubmed: 26742998
doi: 10.3322/caac.21332
Tan Z, Huang H, Sun W, Li Y, Jia Y. Current progress of ferroptosis study in ovarian cancer. Front Mol Biosci. 2022;9: 966007.
pubmed: 36090052
pmcid: 9458863
doi: 10.3389/fmolb.2022.966007
Jin D, Jiang Y, Chang L, Wei J, Sun J. New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases. Int Immunopharmacol. 2022;110: 108935.
pubmed: 35732097
doi: 10.1016/j.intimp.2022.108935
Moleiro ML, Gouveia AB. Extra-abdominal lymph node metastases as the first presentation in ovarian and fallopian tube carcinomas. Reprod Sci. 2023;30:1017–32.
pubmed: 35941512
doi: 10.1007/s43032-022-01049-z
Zhang Z, Huang J, Zhang C, Yang H, Qiu H, Li J, et al. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Cancer Gene Ther. 2015;22:198–206.
pubmed: 25721210
doi: 10.1038/cgt.2015.7
He XY, Xu Y, Xia QJ, Zhao XM, Li S, He XQ, et al. Combined scutellarin and C(18)H(17)NO(6) imperils the survival of glioma: partly associated with the repression of PSEN1/PI3K-AKT signaling axis. Front Oncol. 2021;11: 663262.
pubmed: 34568005
pmcid: 8460401
doi: 10.3389/fonc.2021.663262
Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6:268–86.
pubmed: 27471668
pmcid: 4951594
doi: 10.1016/j.apsb.2016.05.013
Yang Y, Yan R, Zhang L, Meng X, Sun W. Primary glioblastoma transcriptome data analysis for screening survival-related genes. J Cell Biochem. 2020;121:1901–10.
pubmed: 31633244
doi: 10.1002/jcb.29425
Ruiz MF, Gennaro MV, Bastone LC, Godoy AR, Torruella M, Perez GR. Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas. Mol Clin Oncol. 2021;15:150.
pubmed: 34141429
pmcid: 8204142
doi: 10.3892/mco.2021.2312
Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, et al. Designing clinical trials for combination immunotherapy: a framework for glioblastoma. Clin Cancer Res. 2022;28:585–93.
pubmed: 34561270
doi: 10.1158/1078-0432.CCR-21-2681
van Bodegraven EJ, Sluijs JA, Tan AK, Robe P, Hol EM. New GFAP splice isoform (GFAPmicro) differentially expressed in glioma translates into 21 kDa N-terminal GFAP protein. FASEB J. 2021;35: e21389.
pubmed: 33583081
doi: 10.1096/fj.202001767R
Muller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6:247.
doi: 10.1126/scitranslmed.3009095
Allen GM, Frankel NW, Reddy NR, Bhargava HK, Yoshida MA, Stark SR, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378:1624.
doi: 10.1126/science.aba1624
Dong L, Tian X, Zhao Y, Tu H, Wong A, Yang Y. The roles of MiRNAs (MicroRNAs) in melanoma immunotherapy. Int J Mol Sci. 2022;23:14775.
pubmed: 36499102
pmcid: 9736803
doi: 10.3390/ijms232314775
Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018;2:11123.
Ralli M, Botticelli A, Visconti IC, Angeletti D, Fiore M, Marchetti P, et al. Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions. J Immunol Res. 2020;2020:9235638.
pubmed: 32671117
pmcid: 7338969
doi: 10.1155/2020/9235638
Pal I, Ramsey JD. The role of the lymphatic system in vaccine trafficking and immune response. Adv Drug Deliv Rev. 2011;63:909–22.
pubmed: 21683103
doi: 10.1016/j.addr.2011.05.018
Aldahhan R, Almohazey D, Khan FA. Emerging trends in the application of gold nanoformulations in colon cancer diagnosis and treatment. Semin Cancer Biol. 2022;86:1056–65.
pubmed: 34843989
doi: 10.1016/j.semcancer.2021.11.008
Dey A, Mitra A, Pathak S, Prasad S, Zhang AS, Zhang H, et al. Recent advancements, limitations, and future perspectives of the use of personalized medicine in treatment of colon cancer. Technol Cancer Res Treat. 2023;22:15330338231178404.
pubmed: 37248615
pmcid: 10240881
doi: 10.1177/15330338231178403
Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024;390:1949–58.
pubmed: 38838311
doi: 10.1056/NEJMoa2400634
Khan FA, Albalawi R, Pottoo FH. Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment. Med Res Rev. 2022;42:227–58.
pubmed: 33891325
doi: 10.1002/med.21809
Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the Ipilimumab approval decennial. Nat Rev Drug Discovery. 2022;21:509–28.
pubmed: 34937915
doi: 10.1038/s41573-021-00345-8
Zhao P, Xu Y, Ji W, Li L, Qiu L, Zhou S, et al. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy. Int J Nanomedicine. 2022;17:73–89.
pubmed: 35027827
pmcid: 8752078
doi: 10.2147/IJN.S346044